PMGC unit NorthStrive transfers EL-32 cell bank to US fermentation facility

Reuters04-13 19:32
PMGC unit NorthStrive transfers EL-32 cell bank to US fermentation facility
  • NorthStrive Biosciences, wholly owned by PMGC Holdings, transferred EL-32 working cell bank to a US third-party fermentation facility to start manufacturing optimization.
  • Program targets higher yield and a scalable process to support IND-enabling work for EL-32.
  • Modulant Biosciences, NorthStrive licensee for non-human animal health uses, retained facility to run upstream and downstream process development.
  • NorthStrive kept rights for human therapeutic applications while Modulant holds exclusive rights for non-human animal health products.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief on April 12, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment